AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion - statnews.com
AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion statnews.com
Eli Lilly Company News
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market - CNBC
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market CNBC
Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly - Reuters
Insilico Medicine secures $2.75 billion drug collaboration with Eli Lilly Reuters
Eli Lilly Links to ESPN’s Pat Summitt Reunion Special, Seeking New Ways to Tell Medical Stories - variety.com
Eli Lilly Links to ESPN’s Pat Summitt Reunion Special, Seeking New Ways to Tell Medical Stories variety.com
Jefferies Remains a Buy on Eli Lilly and Company (LLY) - Yahoo! Finance Canada
Jefferies Remains a Buy on Eli Lilly and Company (LLY) Yahoo! Finance Canada
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis | Eli Lilly and Company - Eli Lilly
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis | Eli Lilly and Company Eli Lilly
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech - Financial Times
Eli Lilly to sign $2bn deal for AI drug development with Hong Kong biotech Financial Times
Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion - Bloomberg.com
Lilly, Insilico Ink Deal on AI Drugs Worth Up to $2.75 Billion Bloomberg.com
Jefferies Remains a Buy on Eli Lilly and Company (LLY) - Insider Monkey
Jefferies Remains a Buy on Eli Lilly and Company (LLY) Insider Monkey
1 Reason Eli Lilly Stock Is Still a Buy - The Motley Fool
1 Reason Eli Lilly Stock Is Still a Buy The Motley Fool
Eli Lilly PsA Trial Links Dual Therapy Success With Valuation Upside Potential - simplywall.st
Eli Lilly PsA Trial Links Dual Therapy Success With Valuation Upside Potential simplywall.st
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus - TechStock²
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus TechStock²
Eli Lilly and Company (NYSE:LLY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Eli Lilly and Company (NYSE:LLY) Rating Increased to Strong-Buy at Wall Street Zen MarketBeat
Eli Lilly Shares Acquired by World Investment Advisors - National Today
Eli Lilly Shares Acquired by World Investment Advisors National Today
US pharma giant Eli Lilly, Insilico Medicine secure deal worth $2.75 billion to bring AI-developed drugs to market - Mint
US pharma giant Eli Lilly, Insilico Medicine secure deal worth $2.75 billion to bring AI-developed drugs to market Mint
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits
MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation Stocktwits
How an outsider crept into Eli Lilly’s top ranks — and plans to drive its business forward - statnews.com
How an outsider crept into Eli Lilly’s top ranks — and plans to drive its business forward statnews.com
Eli Lilly targets Civil War-era whistleblower law at US Supreme Court - Reuters
Eli Lilly targets Civil War-era whistleblower law at US Supreme Court Reuters
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - Eli Lilly
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 Eli Lilly
Cadent Capital Advisors Boosts Eli Lilly Stake by 217.5% - National Today
Cadent Capital Advisors Boosts Eli Lilly Stake by 217.5% National Today
Could Buying Eli Lilly Today Set You Up for Life? - AOL.com
Could Buying Eli Lilly Today Set You Up for Life? AOL.com
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance - Eli Lilly
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance Eli Lilly
Eli Lilly, UOB & Microsoft: This Week's Top Health Stories - Healthcare Digital
Eli Lilly, UOB & Microsoft: This Week's Top Health Stories Healthcare Digital
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients | Eli Lilly and Company - Eli Lilly
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients | Eli Lilly and Company Eli Lilly
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance - Eli Lilly
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance Eli Lilly
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility - Eli Lilly
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility Eli Lilly
Why is Eli Lilly stock down today? - Traders Union
Why is Eli Lilly stock down today? Traders Union
Assenagon Asset Management S.A. Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Position in Eli Lilly and Company $LLY MarketBeat
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI | Eli Lilly and Company - Eli Lilly
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI | Eli Lilly and Company Eli Lilly
Statement: America’s leading role in biopharmaceutical innovation | Eli Lilly and Company - Eli Lilly
Statement: America’s leading role in biopharmaceutical innovation | Eli Lilly and Company Eli Lilly
Sen. Angus S. King Jr. Sells Off Shares of Eli Lilly and Company (NYSE:LLY) - MarketBeat
Sen. Angus S. King Jr. Sells Off Shares of Eli Lilly and Company (NYSE:LLY) MarketBeat
Janus Henderson Forty Fund’s Updates on Eli Lilly and Company (LLY) - Yahoo Finance
Janus Henderson Forty Fund’s Updates on Eli Lilly and Company (LLY) Yahoo Finance
Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company - Eli Lilly
Lilly to acquire Orna Therapeutics to advance cell therapies | Eli Lilly and Company Eli Lilly
Vanguard disaggregation: Eli Lilly (NYSE: LLY) ownership shows 0 shares - Stock Titan
Vanguard disaggregation: Eli Lilly (NYSE: LLY) ownership shows 0 shares Stock Titan
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company - Eli Lilly
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama | Eli Lilly and Company Eli Lilly
Overbrook Management Corp Has $30.40 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Overbrook Management Corp Has $30.40 Million Stock Position in Eli Lilly and Company $LLY MarketBeat
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans - Eli Lilly
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans Eli Lilly
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company - Eli Lilly
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company Eli Lilly
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company - Eli Lilly
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company Eli Lilly